RA
KPRX icon

Rosalind Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

Rosalind Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-250,059
Closed -$753K – 41
2025
Q1 		$753K Sell
250,059
-496
-0.2% -$1.72K 0.37% 28
2024
Q4 		$827K Sell
250,555
-5,000
-2% -$17.3K 0.42% 28
2024
Q3 		$935K Hold
255,555
– – 0.6% 24
2024
Q2 		$1.07M Sell
255,555
-1
-0% -$5 0.83% 24
2024
Q1 		$1.62M Buy
+255,556
New +$1.43M 1.52% 22

Other funds holding KPRX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rosalind Advisors's KPRX Position: Q2 2025 in Review

Rosalind Advisors sold out of Kiora Pharmaceuticals (KPRX) in Q2 2025, closing a stake of 250,059 shares — an estimated $753K sold.

Rosalind Advisors first reported a position in KPRX in Q1 2024 and held it in 5 quarters. The position peaked at $1.62M in Q1 2024. 16 funds tracked by Wall St. Rank hold KPRX as of Q2 2025.

  • Rosalind Advisors reported no remaining Kiora Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Rosalind Advisors sold 250,059 Kiora Pharmaceuticals shares in Q2 2025, an estimated $753K.
  • Rosalind Advisors first reported a position in Kiora Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Rosalind Advisors's Kiora Pharmaceuticals position peaked at $1.62M in Q1 2024.
  • 16 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2025.

Based on Rosalind Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.